Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 6/20 | 0.40 |
| ▸ | CD74 | P04233 | 4/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544032 | 0.94 | SIGMAR1 (0.40) | SIGMAR1MIF | |
| SCHEMBL2540918 | 0.89 | POLB (0.54) | SIGMAR1KMT2AMEN1POLBMIF | |
| SCHEMBL2542689 | 0.88 | SIGMAR1 (0.54) | SIGMAR1KMT2ANOS3NOS1NOS2 | |
| SCHEMBL2546966 | 0.88 | TP53 (0.48) | KMT2AMEN1POLBMIF | |
| SCHEMBL2544317 | 0.87 | MAPT (0.43) | SIGMAR1KMT2AMEN1POLBMIF | |
| SCHEMBL2540729 | 0.86 | MIF (0.55) | POLBMIFCD74 | |
| SCHEMBL2547731 | 0.86 | KMO (0.46) | SIGMAR1KMT2AMEN1POLBMIF | |
| SCHEMBL3730374 | 0.86 | MIF (0.41) | SIGMAR1KMT2AMEN1POLBMIF | |
| SCHEMBL2542601 | 0.86 | SIGMAR1 (0.42) | SIGMAR1KMT2AMEN1POLBMIF | |
| SCHEMBL2540868 | 0.85 | IDO1 (0.40) | SIGMAR1KMT2AMEN1POLBMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263596-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | SCHADT OLIVER | 2011-10-27 | — | — | US | claimed |
| US-20110263596-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | SCHADT OLIVER | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263596-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | MET, RET, ERBB2 | SIGMAR1 3648/4885KMT2A 794/4885MEN1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.